Therapeutic Approaches to Genetic Diseases Study Section – TAG
TAG study section covers mechanisms by which genome abnormalities that cause rare genetic disease lead to disease pathogenesis. TAG reviews applications focused on molecular pathogenesis and therapies of rare diseases as multi-organ diseases. Further, the study section covers development of therapeutics for genetic diseases. TAG reviews applications focused on molecular pathogenesis and therapies of rare diseases as multi-organ diseases; applications focused on specific organ biology and systems are reviewed in respective organ/disease study sections.
Review Dates
Topics
- Molecular and cellular mechanisms and functional characterization of genomic abnormalities involved in genetic disease pathogenesis.
- Development of genetic disease therapies: cellular and gene therapies, transfer, replacement and correction of genes, changes of gene expression through silencing or activation, and enzyme replacement and substrate reduction therapies.
- Development of resources to study mechanisms and therapies of genetic diseases: stem cells, nucleic acid transfer vectors, and animal models of human diseases.
- Preclinical studies of genetic disease therapies.
Shared Interests and Overlaps
There are shared interests in rare genetic disease with Genetics of Health and Disease (GHD). Applications that focus on the molecular mechanisms by which genomic abnormalities lead to rare genetic disease pathogenesis and the development of therapeutics for genetic diseases are reviewed in TAG. Applications that focus on the discovery, application and interpretation of genomic variation with respect to rare genetic diseases are reviewed in GHD.
There are shared interests in neurological disease with Molecular Neurogenetics (MNG). Applications focused on the neuroscience context of rare diseases may be reviewed by MNG. Studies focused on molecular mechanisms of pathogenesis of rare diseases with neurological pathology may be reviewed by TAG.
There are shared interests in therapy development with Advancing Therapeutics B (ATB). Applications focused on optimization of therapeutic compound efficacy and pharmacokinetic/pharmacodynamic and toxicity studies may be reviewed by ATB. Studies focused on discovery and early development of gene therapies of genetic diseases may be reviewed by TAG.
Other neuroscience study sections may review applications focused on molecular neurology of rare diseases. Applications that focus on the molecular mechanisms of neurological pathogenesis and therapies for rare disease may be reviewed by TAG.
Other organ disease focused study sections may review applications studying pathogenesis and treatments for rare diseases related to their respective organ. Applications that focus on molecular pathogenesis and therapies of rare diseases as multi-organ diseases may be reviewed by TAG.
